Irbesartan Al (Irbesartan)

Irbesartan selectively blocks the AT1 subtype of angiotensin II receptors, preventing angiotensin II from binding and activating the receptor. This inhibition reduces vasoconstriction, aldosterone secretion, and sympathetic activation, leading to vasodilation, decreased sodium and water retention, and ultimately lower blood pressure and reduced renal stress.

The appropriate dose of Irbesartan Al is determined by the prescribing healthcare professional based on the individual’s blood pressure, renal function, and concomitant medications. Dosage may be adjusted after monitoring response and tolerability, and patients should follow the prescriber’s instructions without altering the regimen on their own.

Irbesartan is classified as pregnancy category D, indicating evidence of risk to the fetus and it should be avoided during pregnancy. It is also excreted in breast milk, so breastfeeding is not recommended while using this medication. Alternative therapies should be discussed with a healthcare provider.

To place an order, submit an enquiry on the Irbesartan Al product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to Irbesartan is the ACE‑inhibitor class, such as enalapril. Both lower blood pressure by interfering with the renin‑angiotensin system, but ARBs like Irbesartan are generally better tolerated, with a lower incidence of cough and angio‑edema. Choice depends on patient tolerance, comorbidities and physician preference.

Irbesartan Al tablets should be stored at ambient temperature below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Irbesartan Al is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Patients should be alert for signs of serious adverse reactions such as angio‑edema (swelling of the face, lips, tongue or throat), severe hypotension, marked increase in blood potassium levels, or sudden decline in kidney function. Immediate medical attention is required if any of these symptoms occur.

Irbesartan Al is contraindicated in individuals with known hypersensitivity to Irbesartan or any component of the formulation, in patients with severe hepatic impairment, and in pregnant women. Caution is also advised for patients with severe renal impairment or those taking potassium‑sparing diuretics.